Skip to search formSkip to main contentSkip to account menu

apolizumab

Known as: Monoclonal Antibody Hu1D10, MOAB Hu1D10, Monoclonal antibody 1D10 
A humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic… 
National Institutes of Health

Related topics

Related topics

10 relations

Broader (2)

Antibodies, Monoclonal, HumanizedMonoclonal Antibodies
Antibody-Dependent Cellular CytotoxicityB-LymphocytesComplement-Dependent CytotoxicityHLA-DR Antigens

Narrower (2)

Hu1D 10Remitogen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab
Background:Apolizumab (APO) is a humanized IgG1 antibody targeting a HLA-DRβ chain specific epitope, which is expressed by approx… 
2009
2009
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia
Apolizumab (Hu1D10), a humanized monoclonal anti- Human leukocyte antigen -DR β-chain antibody, mediates apoptosis of chronic… 
Review
2008
Review
2008
Newer monoclonal antibodies for hematological malignancies.
2008
2008
Caracterização funcional do anticorpo monoclonal humano BH1
Embora, existam novas terapias e avancos no tratamento do cancro, por vezes, os beneficios esperados nao sao alcancados. O drama… 
2006
2006
A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: A pilot study
Apolizumab is a humanized monoclonal antibody against a polymorphic epitope on HLA DRβ that demonstrated evidence for therapeutic… 
2005
2005
Phase 1 study of combination rituximab with apolizumab in relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia
6607 Background: Apolizumab (Apo), a humanized IgG1 mAb, targets ID10, and rituximab (R), a chimeric IgG1 mAb, targets CD20, both… 
2005
2005
In Vitro Activity of the Humanized Anti-HLA-DR Antibodies KRN848 and Apolizumab in Non-Hodgkins Lymphoma Cell Lines.
Apolizumab (Hu1D10) and KRN848 are humanized IgG1 anti-HLA-DR monoclonal antibodies (mAb). Apolizumab binds a polymorphic… 
Review
2003
Review
2003
Monoclonal antibody therapy of chronic lymphocytic leukemia.
Chemotherapeutic approaches during the last decade have failed to result in major advances in the outcome of patients with… 
2002
2002
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
Clinical activity of anti-CD20 monoclonal antibodies both in the unlabeled (rituximab [Rituxan; Genentech, Inc, South San… 
Review
2002
Review
2002
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
Clinical activity of anti-CD20 monoclonal antibodies both in the unlabeled (rituximab [Rituxan; Genentech, Inc, South San… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)